story of the week
Veliparib Alone or With Carboplatin for BRCA-Associated Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of the PARP Inhibitor Veliparib With Carboplatin or as a Single Agent in Patients With Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer
Clin. Cancer Res 2017 Mar 29;[EPub Ahead of Print], G Somlo, P Frankel, B Arun, CX Ma, A Garcia, T Cigler, L Cream, H Harvey, JA Sparano, R Nanda, HK Chew, T Moynihan, MP Goetz, L Vahdat, JH Beumer, A Hurria, J Mortimer, R Piekarz, S Sand, J Herzog, LR Van Tongeren, K Ferry-Galow, A Chen, C Ruel, E Newman, DR Gandara, JN WeitzelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.